Aktienanalyse zu Sangamo Therapeutics Inc (SGMO)SGMOSangamo Therapeutics Inc

Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Sangamo Therapeutics Inc (SGMO) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. While the company has shown significant revenue growth in its latest quarter, the stock's technical indicators are bearish, and there are no strong positive catalysts or trading signals to suggest immediate upside potential. The options data and lack of recent news or significant insider activity further support a cautious approach.

6 analysts cover SGMO: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 3.75.